Molecular Partners AG (MOLN)
Molecular Partners AG Statistics
Share Statistics
Molecular Partners AG has 36.87M shares outstanding. The number of shares has increased by 11.13% in one year.
Shares Outstanding | 36.87M |
Shares Change (YoY) | 11.13% |
Shares Change (QoQ) | 0.03% |
Owned by Institutions (%) | 10.79% |
Shares Floating | 36.77M |
Failed to Deliver (FTD) Shares | 22 |
FTD / Avg. Volume | 0.59% |
Short Selling Information
The latest short interest is 44.78K, so 0.12% of the outstanding shares have been sold short.
Short Interest | 44.78K |
Short % of Shares Out | 0.12% |
Short % of Float | 0.12% |
Short Ratio (days to cover) | 5.49 |
Valuation Ratios
The PE ratio is -2.65 and the forward PE ratio is -3.24. Molecular Partners AG's PEG ratio is 0.19.
PE Ratio | -2.65 |
Forward PE | -3.24 |
PS Ratio | 28.8 |
Forward PS | 1.2 |
PB Ratio | 1.01 |
P/FCF Ratio | -2.39 |
PEG Ratio | 0.19 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Molecular Partners AG.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.31, with a Debt / Equity ratio of 0.02.
Current Ratio | 14.31 |
Quick Ratio | 14.31 |
Debt / Equity | 0.02 |
Debt / EBITDA | -0.05 |
Debt / FCF | -0.04 |
Interest Coverage | -2448.68 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $31.46K |
Profits Per Employee | $-342.04K |
Employee Count | 158 |
Asset Turnover | 0.03 |
Inventory Turnover | n/a |
Taxes
Income Tax | 2K |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 1.79% in the last 52 weeks. The beta is 0.63, so Molecular Partners AG's price volatility has been higher than the market average.
Beta | 0.63 |
52-Week Price Change | 1.79% |
50-Day Moving Average | 4.74 |
200-Day Moving Average | 5.6 |
Relative Strength Index (RSI) | 38.68 |
Average Volume (20 Days) | 3.71K |
Income Statement
In the last 12 months, Molecular Partners AG had revenue of 4.97M and earned -54.04M in profits. Earnings per share was -1.63.
Revenue | 4.97M |
Gross Profit | 4.97M |
Operating Income | -61.22M |
Net Income | -54.04M |
EBITDA | -51.65M |
EBIT | -54.02M |
Earnings Per Share (EPS) | -1.63 |
Balance Sheet
The company has 63.87M in cash and 2.44M in debt, giving a net cash position of 61.43M.
Cash & Cash Equivalents | 63.87M |
Total Debt | 2.44M |
Net Cash | 61.43M |
Retained Earnings | -246.29M |
Total Assets | 158.53M |
Working Capital | 143.5M |
Cash Flow
In the last 12 months, operating cash flow was -59.25M and capital expenditures -723K, giving a free cash flow of -59.97M.
Operating Cash Flow | -59.25M |
Capital Expenditures | -723K |
Free Cash Flow | -59.97M |
FCF Per Share | -1.81 |
Margins
Gross margin is 100%, with operating and profit margins of -1231.73% and -1087.38%.
Gross Margin | 100% |
Operating Margin | -1231.73% |
Pretax Margin | -1087.34% |
Profit Margin | -1087.38% |
EBITDA Margin | -1039.18% |
EBIT Margin | -1231.73% |
FCF Margin | -1206.66% |
Dividends & Yields
MOLN does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for MOLN.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Scores
Altman Z-Score | 2.81 |
Piotroski F-Score | 2 |